Monteforce-AL Tablets

Product Description

Monteforce-AL combines an antihistamine, a leukotriene receptor antagonist and sustained-release ambroxol. It is intended for prescription use in selected allergic respiratory conditions accompanied by cough or mucus congestion.

Levocetirizine targets histamine-mediated allergy symptoms, montelukast modulates leukotriene pathways and ambroxol supports mucus clearance. The combination should be used only when a clinician considers all three components appropriate.

Composition / Nutritional Information

• Montelukast — 10 mg
• Levocetirizine Dihydrochloride IP — 5 mg
• Ambroxol Hydrochloride IP (sustained release) — 75 mg
• Excipients — q.s.

Indications / Intended Support

• Allergic rhinitis with respiratory symptoms
• Productive cough with allergy when prescribed
• Chest congestion
• Allergic airway conditions

Key Product Features

• Combines allergy control with mucolytic support
• Sustained-release ambroxol
• May support respiratory comfort
• Prescription-based combination therapy